Do analysts prefer ESLA or INDP?

Estrella Immunopharma currently has a consensus target price of $8.00, indicating a potential upside of 1,006.50%. Given Estrella Immunopharma's stronger consensus rating and higher probable upside, research analysts plainly believe Estrella Immunopharma is more favorable than Indaptus Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Estrella Immunopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, ESLA or INDP?

Estrella Immunopharma is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Estrella Immunopharma N/A N/A -$13.06M -$0.24 N/A Indaptus Therapeutics N/A N/A -$20.85M -$6.33 N/A

Is ESLA or INDP more profitable?

Estrella Immunopharma's return on equity of 0.00% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Estrella Immunopharma N/A N/A -328.72% Indaptus Therapeutics N/A -302.89% -203.49%

Does the media favor ESLA or CBUS?

In the previous week, Cibus had 7 more articles in the media than Estrella Immunopharma. MarketBeat recorded 8 mentions for Cibus and 1 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 0.00 beat Cibus' score of -0.28 indicating that Estrella Immunopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Estrella Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cibus 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ESLA or INO more profitable?

Estrella Immunopharma's return on equity of 0.00% beat Inovio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Estrella Immunopharma N/A N/A -328.72% Inovio Pharmaceuticals N/A -669.94% -73.97%

Does the media refer more to ESLA or INO?

In the previous week, Inovio Pharmaceuticals had 1 more articles in the media than Estrella Immunopharma. MarketBeat recorded 2 mentions for Inovio Pharmaceuticals and 1 mentions for Estrella Immunopharma. Inovio Pharmaceuticals' average media sentiment score of 1.00 beat Estrella Immunopharma's score of 0.00 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Estrella Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inovio Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, BDTX or ESLA?

Estrella Immunopharma is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Black Diamond Therapeutics N/A N/A $22.37M -$0.75 N/A Estrella Immunopharma N/A N/A -$13.06M -$0.24 N/A

Is BDTX or ESLA more profitable?

Estrella Immunopharma's return on equity of 0.00% beat Black Diamond Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Black Diamond Therapeutics N/A -32.10% -25.21% Estrella Immunopharma N/A N/A -328.72%

Is ESLA or GNLX more profitable?

Estrella Immunopharma's return on equity of 0.00% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Estrella Immunopharma N/A N/A -328.72% Genelux N/A -205.85% -138.79%

Does the media refer more to ESLA or GNLX?

In the previous week, Genelux had 21 more articles in the media than Estrella Immunopharma. MarketBeat recorded 22 mentions for Genelux and 1 mentions for Estrella Immunopharma. Genelux's average media sentiment score of 0.45 beat Estrella Immunopharma's score of 0.00 indicating that Genelux is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Estrella Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genelux 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Estrella Immunopharma (ESLA) Competitors

$0.72 -0.01 (-1.67%)

As of 03:43 PM Eastern

Compare

ESLA vs. INDP, CBUS, INO, BDTX, and GNLX

Should you buy Estrella Immunopharma stock or one of its competitors? Estrella Immunopharma's main competitors and comparable companies include Indaptus Therapeutics (INDP), Cibus (CBUS), Inovio Pharmaceuticals (INO), Black Diamond Therapeutics (BDTX), and Genelux (GNLX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Estrella Immunopharma compare to Indaptus Therapeutics?

Estrella Immunopharma (NASDAQ:ESLA) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

Estrella Immunopharma is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.24	N/A
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$6.33	N/A

Estrella Immunopharma's return on equity of 0.00% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Estrella Immunopharma	N/A	N/A	-328.72%
Indaptus Therapeutics	N/A	-302.89%	-203.49%

Estrella Immunopharma has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market.

Estrella Immunopharma currently has a consensus target price of $8.00, indicating a potential upside of 1,006.50%. Given Estrella Immunopharma's stronger consensus rating and higher probable upside, research analysts plainly believe Estrella Immunopharma is more favorable than Indaptus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

0.3% of Estrella Immunopharma shares are owned by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are owned by institutional investors. 5.8% of Estrella Immunopharma shares are owned by company insiders. Comparatively, 9.9% of Indaptus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Estrella Immunopharma had 1 more articles in the media than Indaptus Therapeutics. MarketBeat recorded 1 mentions for Estrella Immunopharma and 0 mentions for Indaptus Therapeutics. Estrella Immunopharma's average media sentiment score of 0.00 equaled Indaptus Therapeutics'average media sentiment score.

Company	Overall Sentiment
Estrella Immunopharma	Neutral
Indaptus Therapeutics	Neutral

Summary

Estrella Immunopharma beats Indaptus Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Estrella Immunopharma compare to Cibus?

Estrella Immunopharma (NASDAQ:ESLA) and Cibus (NASDAQ:CBUS) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

0.3% of Estrella Immunopharma shares are owned by institutional investors. Comparatively, 33.8% of Cibus shares are owned by institutional investors. 5.8% of Estrella Immunopharma shares are owned by company insiders. Comparatively, 29.9% of Cibus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Estrella Immunopharma has higher earnings, but lower revenue than Cibus. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Cibus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.24	N/A
Cibus	$4.35M	30.14	-$127.08M	-$1.65	N/A

Estrella Immunopharma has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, Cibus has a beta of 1.61, suggesting that its share price is 61% more volatile than the broader market.

Estrella Immunopharma has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. Estrella Immunopharma's return on equity of 0.00% beat Cibus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Estrella Immunopharma	N/A	N/A	-328.72%
Cibus	-2,258.89%	-287.03%	-27.99%

Estrella Immunopharma currently has a consensus target price of $8.00, suggesting a potential upside of 1,006.50%. Cibus has a consensus target price of $9.00, suggesting a potential upside of 425.09%. Given Estrella Immunopharma's higher possible upside, equities analysts clearly believe Estrella Immunopharma is more favorable than Cibus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cibus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Cibus had 7 more articles in the media than Estrella Immunopharma. MarketBeat recorded 8 mentions for Cibus and 1 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 0.00 beat Cibus' score of -0.28 indicating that Estrella Immunopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Estrella Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cibus	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Cibus beats Estrella Immunopharma on 7 of the 13 factors compared between the two stocks.

How does Estrella Immunopharma compare to Inovio Pharmaceuticals?

Estrella Immunopharma (NASDAQ:ESLA) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

Estrella Immunopharma has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market. Comparatively, Inovio Pharmaceuticals has a beta of 1.52, meaning that its share price is 52% more volatile than the broader market.

Estrella Immunopharma presently has a consensus target price of $8.00, suggesting a potential upside of 1,006.50%. Inovio Pharmaceuticals has a consensus target price of $3.17, suggesting a potential upside of 152.32%. Given Estrella Immunopharma's higher probable upside, research analysts clearly believe Estrella Immunopharma is more favorable than Inovio Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Inovio Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Estrella Immunopharma has higher earnings, but lower revenue than Inovio Pharmaceuticals. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.24	N/A
Inovio Pharmaceuticals	$60K	2,162.78	-$84.95M	-$0.91	N/A

Estrella Immunopharma's return on equity of 0.00% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Estrella Immunopharma	N/A	N/A	-328.72%
Inovio Pharmaceuticals	N/A	-669.94%	-73.97%

0.3% of Estrella Immunopharma shares are held by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are held by institutional investors. 5.8% of Estrella Immunopharma shares are held by company insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Inovio Pharmaceuticals had 1 more articles in the media than Estrella Immunopharma. MarketBeat recorded 2 mentions for Inovio Pharmaceuticals and 1 mentions for Estrella Immunopharma. Inovio Pharmaceuticals' average media sentiment score of 1.00 beat Estrella Immunopharma's score of 0.00 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Estrella Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inovio Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Inovio Pharmaceuticals beats Estrella Immunopharma on 10 of the 15 factors compared between the two stocks.

How does Estrella Immunopharma compare to Black Diamond Therapeutics?

Black Diamond Therapeutics (NASDAQ:BDTX) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 0.3% of Estrella Immunopharma shares are owned by institutional investors. 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Comparatively, 5.8% of Estrella Immunopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Estrella Immunopharma's return on equity of 0.00% beat Black Diamond Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-32.10%	-25.21%
Estrella Immunopharma	N/A	N/A	-328.72%

In the previous week, Estrella Immunopharma had 1 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 1 mentions for Estrella Immunopharma and 0 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 0.00 equaled Estrella Immunopharma'saverage media sentiment score.

Company	Overall Sentiment
Black Diamond Therapeutics	Neutral
Estrella Immunopharma	Neutral

Estrella Immunopharma is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	N/A	N/A	$22.37M	-$0.75	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.24	N/A

Black Diamond Therapeutics presently has a consensus target price of $9.80, indicating a potential upside of 354.76%. Estrella Immunopharma has a consensus target price of $8.00, indicating a potential upside of 1,006.50%. Given Estrella Immunopharma's higher probable upside, analysts plainly believe Estrella Immunopharma is more favorable than Black Diamond Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Black Diamond Therapeutics has a beta of 3.28, meaning that its share price is 228% more volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

Summary

Black Diamond Therapeutics beats Estrella Immunopharma on 8 of the 12 factors compared between the two stocks.

How does Estrella Immunopharma compare to Genelux?

Estrella Immunopharma (NASDAQ:ESLA) and Genelux (NASDAQ:GNLX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations.

In the previous week, Genelux had 21 more articles in the media than Estrella Immunopharma. MarketBeat recorded 22 mentions for Genelux and 1 mentions for Estrella Immunopharma. Genelux's average media sentiment score of 0.45 beat Estrella Immunopharma's score of 0.00 indicating that Genelux is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Estrella Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genelux	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Estrella Immunopharma's return on equity of 0.00% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Estrella Immunopharma	N/A	N/A	-328.72%
Genelux	N/A	-205.85%	-138.79%

Estrella Immunopharma has higher earnings, but lower revenue than Genelux. Genelux is trading at a lower price-to-earnings ratio than Estrella Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.24	N/A
Genelux	$10K	12,323.38	-$32.15M	-$0.86	N/A

Estrella Immunopharma has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market. Comparatively, Genelux has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market.

Estrella Immunopharma currently has a consensus price target of $8.00, indicating a potential upside of 1,006.50%. Genelux has a consensus price target of $18.00, indicating a potential upside of 560.79%. Given Estrella Immunopharma's higher possible upside, research analysts clearly believe Estrella Immunopharma is more favorable than Genelux.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

0.3% of Estrella Immunopharma shares are owned by institutional investors. Comparatively, 37.3% of Genelux shares are owned by institutional investors. 5.8% of Estrella Immunopharma shares are owned by company insiders. Comparatively, 7.5% of Genelux shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Genelux beats Estrella Immunopharma on 8 of the 14 factors compared between the two stocks.

Get Estrella Immunopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ESLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ESLA vs. The Competition

Export

Metric	Estrella Immunopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$31.41M	$3.99B	$7.29B	$12.73B
Dividend Yield	N/A	3.64%	2.54%	10.79%
P/E Ratio	-3.01	11.76	271.37	24.13
Price / Sales	N/A	1,299.21	605.97	78.27
Price / Cash	N/A	44.94	29.03	36.90
Price / Book	-2.68	17.27	11.19	6.40
Net Income	-$13.06M	-$22.72M	$3.46B	$348.39M
7 Day Performance	-4.89%	2.96%	2.07%	1.09%
1 Month Performance	-7.31%	9.80%	7.40%	5.27%
1 Year Performance	-25.46%	54.94%	24.84%	16.29%

Estrella Immunopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ESLA Estrella Immunopharma	1.7044 of 5 stars	$0.72 -1.7%	$8.00 +1,006.5%	-24.2%	$31.41M	N/A	N/A	N/A	Gap Up
INDP Indaptus Therapeutics	0.737 of 5 stars	$0.94 +0.4%	N/A	-82.4%	$124.73M	N/A	N/A	6	Gap Down High Trading Volume
CBUS Cibus	1.3995 of 5 stars	$1.70 +4.3%	$9.00 +429.4%	+24.1%	$124.58M	$3.64M	N/A	48
INO Inovio Pharmaceuticals	3.1386 of 5 stars	$1.30 +8.3%	$3.17 +143.6%	-39.8%	$124.08M	$60K	N/A	320
BDTX Black Diamond Therapeutics	1.6234 of 5 stars	$2.19 +6.3%	$9.80 +347.5%	-24.3%	$118.36M	$70M	N/A	90

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ESLA) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Estrella Immunopharma (ESLA) Competitors

ESLA vs. INDP, CBUS, INO, BDTX, and GNLX

How does Estrella Immunopharma compare to Indaptus Therapeutics?

Summary

How does Estrella Immunopharma compare to Cibus?

Summary

How does Estrella Immunopharma compare to Inovio Pharmaceuticals?

Summary

How does Estrella Immunopharma compare to Black Diamond Therapeutics?

Summary

How does Estrella Immunopharma compare to Genelux?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESLA vs. The Competition

Estrella Immunopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Estrella Immunopharma (ESLA) Competitors

ESLA vs. INDP, CBUS, INO, BDTX, and GNLX

How does Estrella Immunopharma compare to Indaptus Therapeutics?

Which has better valuation and earnings, ESLA or INDP?

Is ESLA or INDP more profitable?

Which has more volatility & risk, ESLA or INDP?

Do analysts prefer ESLA or INDP?

Do insiders and institutionals hold more shares of ESLA or INDP?

Does the media favor ESLA or INDP?

Summary

How does Estrella Immunopharma compare to Cibus?

Do institutionals and insiders hold more shares of ESLA or CBUS?

Which has higher earnings & valuation, ESLA or CBUS?

Which has more risk & volatility, ESLA or CBUS?

Is ESLA or CBUS more profitable?

Do analysts prefer ESLA or CBUS?

Does the media favor ESLA or CBUS?

Summary

How does Estrella Immunopharma compare to Inovio Pharmaceuticals?

Which has more volatility and risk, ESLA or INO?

Do analysts rate ESLA or INO?

Which has preferable earnings and valuation, ESLA or INO?

Is ESLA or INO more profitable?

Do institutionals and insiders believe in ESLA or INO?

Does the media refer more to ESLA or INO?

Summary

How does Estrella Immunopharma compare to Black Diamond Therapeutics?

Do institutionals and insiders believe in BDTX or ESLA?

Is BDTX or ESLA more profitable?

Does the media favor BDTX or ESLA?

Which has higher earnings and valuation, BDTX or ESLA?

Do analysts rate BDTX or ESLA?

Which has more risk & volatility, BDTX or ESLA?

Summary

How does Estrella Immunopharma compare to Genelux?

Does the media refer more to ESLA or GNLX?

Is ESLA or GNLX more profitable?

Which has preferable valuation & earnings, ESLA or GNLX?

Which has more volatility & risk, ESLA or GNLX?

Do analysts prefer ESLA or GNLX?

Do institutionals and insiders believe in ESLA or GNLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ESLA vs. The Competition

Estrella Immunopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools